Related Experiment Video
Updated: Jun 13, 2026
07:34
Induction of Acute Ischemic Stroke in Mice Using the Distal Middle Artery Occlusion Technique
Published on: December 15, 2023
Shuxuening injection ameliorates poststroke cognitive impairment by regulating multiple cell death pathways
Jing Lv1, Xufeng Tao2, Yu Wu3
1Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China; College of Pharmacy, Dalian Medical University, Dalian, 116044, China.
Summary
Shuxuening injection (SXNI) effectively treats poststroke cognitive impairment by regulating cell death pathways and reducing oxidative stress in the ischemic brain. This offers a promising therapeutic strategy for acute ischemic stroke (AIS).
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Poststroke cognitive impairment (PSCI) is a common consequence of ischemic stroke (IS).
- The therapeutic effects of Shuxuening injection (SXNI) on PSCI remain largely unexplored despite its use in cardiovascular and cerebrovascular diseases.
Purpose of the Study:
- To investigate the therapeutic effects of SXNI on PSCI.
- To elucidate the molecular mechanisms underlying SXNI's action in acute ischemic stroke (AIS).
Main Methods:
- Multiomics analyses (transcriptomics, proteomics) combined with biochemical assays and electron microscopy.
- Assessment of neurological function, infarct volume, and histopathology.
- Quantitative and qualitative analysis of SXNI components using UPLC-MS/MS and LC-MS/MS.
Main Results:
- SXNI modulates key signaling pathways involved in oxidative stress, immune, and inflammatory responses.
- Integrated multiomics data suggest SXNI's therapeutic role in AIS pathogenesis.
- SXNI was found to suppress pyroptotic and oxeiptotic signaling via the HIF-1α/NLRP3 and KEAP1/PGAM5/AIFM1 axes.
Conclusions:
- SXNI mitigates ischemic brain injury by targeting reactive oxygen species (ROS)-mediated cell death.
- SXNI demonstrates significant potential as a therapeutic strategy for AIS.
- Further research into combining SXNI with other treatments like Edaravone (EDA) is warranted.
